Immunome (IMNM) Equity Ratio (2023 - 2025)
Immunome's Equity Ratio history spans 3 years, with the latest figure at 0.93 for Q4 2025.
- For Q4 2025, Equity Ratio rose 23.13% year-over-year to 0.93; the TTM value through Dec 2025 reached 0.93, up 23.13%, while the annual FY2025 figure was 0.93, 23.13% up from the prior year.
- Equity Ratio reached 0.93 in Q4 2025 per IMNM's latest filing, up from 0.88 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.93 in Q4 2025 to a low of 0.07 in Q3 2023.
- Average Equity Ratio over 3 years is 0.7, with a median of 0.85 recorded in 2024.
- The largest YoY upside for Equity Ratio was 1182.64% in 2024 against a maximum downside of 6.56% in 2024.
- A 3-year view of Equity Ratio shows it stood at 0.81 in 2023, then dropped by 6.56% to 0.75 in 2024, then increased by 23.13% to 0.93 in 2025.
- Per Business Quant, the three most recent readings for IMNM's Equity Ratio are 0.93 (Q4 2025), 0.88 (Q3 2025), and 0.91 (Q2 2025).